Treatment of Stage I or II Oropharyngeal Cancer — Back of Tongue, Soft Palate, or Tonsils (HPV-Positive or HPV-Negative)

This protocol covers early-stage oropharyngeal cancer involving the base of the tongue, soft palate, or tonsils, at stage I or stage II, in both p16/HPV-positive and p16/HPV-negative presentations.

Clinical Scenario

Early-stage oropharyngeal cancers — back of the tongue, soft palate, and tonsils — typically include most stage I and stage II cases. This protocol applies regardless of HPV (p16) status: both HPV-positive and HPV-negative patients at these early stages are addressed.

Treatment Approach (Overview)

When cancer remains or the risk of recurrence is elevated following initial management, concurrent treatment combining chemotherapy with radiation therapy is a recognised approach in this setting. The full protocol specifies which patients qualify, the sequencing, and all further details.

Complete regimen details, eligibility criteria, and decision algorithm are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Early-stage oropharyngeal cancers (back of the tongue, soft palate, and tonsils) typically include most stage I and II cancers, p16/HPV-positive or p16/HPV-negative.
After surgery, if any cancer remains or if there is a high chance of the cancer coming back, chemoradiation is often used.

View source ↗